Miss Angela Casbard
Projects as PI
- A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor - FAKTION CRUK (01/10/2013 - 31/10/2019)
- A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA AZ (01/10/2014 - 14/09/2024)
- A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA CRUK
(01/10/2014 - 30/09/2017) - A randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma - VIM (01/11/2013 - 30/06/2022)
- Evaluation of the safety of CEdiranib in the prevention of bowel perforation in platinum-resistant Ovarian Cancer (CEBOC) (30/11/2017 - 31/12/2023)
Projects as Co-Investigator
- Adjuvant radiotherapy in patients with high-risk primary cutaneous
Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): an open label, multicentre, two-arm phase III randomised trial (01/01/2023 - 31/12/2030) - A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin in the treatment of Cancer Associated Thrombosis (ALICAT) (01/03/2013 - 28/02/2015)
- A phase I/II trial of the mTOR inhibitor temsirolimus (CCI-779; torisel) plus gemcitabine and cisplatin as first-line therapy for metastatic bladder cancer (and other urothelial cell carcinomas) (TOTEM) (01/02/2008 - 31/12/2015)
- A randomised phase II trial of carboplation and gemcitabane +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin - TOUCAN (19/10/2009 - 30/09/2020)
- Cardiff CTU wind down funding, 2023-2025 (01/10/2023 - 30/09/2025)